Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

NCT05546268 is registered in ClinicalTrials.gov with Monte Rosa Therapeutics, Inc as lead sponsor.

NCT NCT05546268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05546268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma
Lead sponsor
Monte Rosa Therapeutics, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 12, 2022
Completion date
November 30, 2027
Enrollment
174 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, high grade neuroendocrine cancer, hr-positive, her2-negative breast cancer, l-myc and n-myc amplified solid tumors, nsclc, nsclc with high or low l-myc or n-myc expression, prostate cancer, sclc